Compare Stocks: MREO, OTLK, TNYA, and KZIA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$11.01 -7.3%	$13.15	$4.86 ▼ $17.40	$154.07M	2.14	302,956 shs	374,255 shs
MREO Mereo BioPharma Group	$0.24 +0.9%	$0.30	$0.20 ▼ $2.37	$38.72M	0.32	1.24 million shs	699,508 shs
OTLK Oncobiologics	$0.66 +2.7%	$1.02	$0.16 ▼ $2.54	$156.76M	0.74	21.90 million shs	3.09 million shs
TNYA Tenaya Therapeutics	$0.65 -1.8%	$0.75	$0.53 ▼ $2.35	$148.22M	2.77	1.68 million shs	2.27 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	-7.32%	-9.46%	-20.68%	-22.90%	+33.45%
MREO Mereo BioPharma Group	+0.87%	-10.14%	-19.93%	-19.80%	-86.26%
OTLK Oncobiologics	+2.69%	+1.88%	-41.49%	-45.80%	-33.88%
TNYA Tenaya Therapeutics	-1.70%	-6.69%	-13.64%	-8.85%	-50.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KZIA Novogen	$11.01 -7.3%	$13.15	$4.86 ▼ $17.40	$154.07M	2.14	302,956 shs	374,255 shs
MREO Mereo BioPharma Group	$0.24 +0.9%	$0.30	$0.20 ▼ $2.37	$38.72M	0.32	1.24 million shs	699,508 shs
OTLK Oncobiologics	$0.66 +2.7%	$1.02	$0.16 ▼ $2.54	$156.76M	0.74	21.90 million shs	3.09 million shs
TNYA Tenaya Therapeutics	$0.65 -1.8%	$0.75	$0.53 ▼ $2.35	$148.22M	2.77	1.68 million shs	2.27 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KZIA Novogen	-7.32%	-9.46%	-20.68%	-22.90%	+33.45%
MREO Mereo BioPharma Group	+0.87%	-10.14%	-19.93%	-19.80%	-86.26%
OTLK Oncobiologics	+2.69%	+1.88%	-41.49%	-45.80%	-33.88%
TNYA Tenaya Therapeutics	-1.70%	-6.69%	-13.64%	-8.85%	-50.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KZIA Novogen	2.71	Moderate Buy	$27.33	148.26% Upside
MREO Mereo BioPharma Group	2.13	Hold	$1.67	581.38% Upside
OTLK Oncobiologics	2.20	Hold	$5.20	686.45% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	516.52% Upside

Current Analyst Ratings Breakdown

Latest MREO, OTLK, TNYA, and KZIA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/19/2026	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underweight
8/14/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
8/13/2026	KZIA Novogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$29.00
8/12/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/11/2026	MREO Mereo BioPharma Group	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1.00
7/28/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/27/2026	OTLK Oncobiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$1.60

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KZIA Novogen	$30K	4,759.99	N/A	N/A	($5.34) per share	-2.06
MREO Mereo BioPharma Group	$500K	78.12	N/A	N/A	$0.26 per share	0.94
OTLK Oncobiologics	$1.35M	119.24	N/A	N/A	($0.60) per share	-1.10
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	-$41.88M	-$0.04	N/A	N/A	N/A	N/A	-74.82%	-64.28%	11/9/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	N/A
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest MREO, OTLK, TNYA, and KZIA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/12/2026	Q2 2026	MREO Mereo BioPharma Group	-$0.01	-$0.01	N/A	-$0.05	$3.50 million	N/A
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KZIA Novogen	N/A	2.87	N/A
MREO Mereo BioPharma Group	N/A	5.88	5.88
OTLK Oncobiologics	N/A	0.81	0.63
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KZIA Novogen	30.89%
MREO Mereo BioPharma Group	62.83%
OTLK Oncobiologics	11.20%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
KZIA Novogen	1.00%
MREO Mereo BioPharma Group	6.50%
OTLK Oncobiologics	1.80%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KZIA Novogen	12	12.97 million	12.84 million	No Data
MREO Mereo BioPharma Group	40	159.69 million	149.31 million	Optionable
OTLK Oncobiologics	20	243.45 million	239.07 million	Optionable
TNYA Tenaya Therapeutics	110	224.23 million	218.56 million	Optionable

MREO, OTLK, TNYA, and KZIA Headlines

Recent News About These Companies

Tenaya Therapeutics Corporate Event Calendar | NASDAQ:TNYA

3 hours ago | benzinga.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $4.00 Average PT from Analysts

September 10 at 3:44 AM | americanbankingnews.com

BlackRock Inc. Acquires New Stake in Tenaya Therapeutics, Inc. $TNYA

September 6, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) Upgraded at Wall Street Zen

September 6, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Sell

September 6, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Tenaya Therapeutics (NASDAQ:TNYA) Cut to Strong Sell at Wall Street Zen

August 29, 2026 | marketbeat.com

1,555,500 Shares in Tenaya Therapeutics, Inc. $TNYA Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Empery Asset Management LP Takes $2.86 Billion Position in Tenaya Therapeutics, Inc. $TNYA

August 22, 2026 | marketbeat.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

August 18, 2026 | marketbeat.com

Tenaya Therapeutics (NASDAQ:TNYA) CEO Sells $15,784.72 in Stock

August 17, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA

August 17, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block

July 13, 2026 | donanimhaber.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO, OTLK, TNYA, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

$11.01 -0.87 (-7.32%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$10.93 -0.08 (-0.72%)

As of 04:00 AM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Mereo BioPharma Group NASDAQ:MREO

$0.24 +0.00 (+0.87%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$0.26 +0.01 (+4.66%)

As of 04:09 AM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Oncobiologics NASDAQ:OTLK

$0.66 +0.02 (+2.69%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.64%)

As of 05:45 AM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Tenaya Therapeutics NASDAQ:TNYA

$0.65 -0.01 (-1.85%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$0.67 +0.02 (+3.42%)

As of 05:46 AM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MREO, OTLK, TNYA, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MREO, OTLK, TNYA, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MREO, OTLK, TNYA, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO, OTLK, TNYA, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

Mereo BioPharma Group NASDAQ:MREO

Oncobiologics NASDAQ:OTLK

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MREO, OTLK, TNYA, and KZIA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MREO, OTLK, TNYA, and KZIA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MREO, OTLK, TNYA, and KZIA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO, OTLK, TNYA, and KZIA Company Descriptions

Novogen NASDAQ:KZIA

Mereo BioPharma Group NASDAQ:MREO

Oncobiologics NASDAQ:OTLK

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools